Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by NEOS Investment Management LLC

NEOS Investment Management LLC increased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.8% in the fourth quarter, Holdings Channel reports. The firm owned 7,962 shares of the medical equipment provider’s stock after purchasing an additional 779 shares during the quarter. NEOS Investment Management LLC’s holdings in Lantheus were worth $712,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new position in Lantheus during the 4th quarter worth approximately $36,183,000. Groupama Asset Managment acquired a new position in Lantheus in the third quarter worth $439,000. Swedbank AB increased its stake in Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after purchasing an additional 385,000 shares during the last quarter. Keybank National Association OH acquired a new stake in shares of Lantheus during the fourth quarter worth $27,526,000. Finally, Janus Henderson Group PLC lifted its position in shares of Lantheus by 7.7% in the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after buying an additional 257,022 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Insider Transactions at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company’s stock, valued at $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,109 shares of company stock valued at $6,110,806. Corporate insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. Truist Financial boosted their price objective on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Finally, B. Riley dropped their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $129.43.

Lantheus Stock Down 0.9 %

Shares of LNTH opened at $96.16 on Monday. The firm has a market capitalization of $6.59 billion, a PE ratio of 16.00 and a beta of 0.38. The firm has a 50-day moving average price of $93.21 and a 200 day moving average price of $96.38. Lantheus Holdings, Inc. has a 52-week low of $58.16 and a 52-week high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.